Lansoprazole Tablet, Orally Disintegrating, Delayed Release
Product Images NDC 65862-895

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 65862-895). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Lansoprazole Fig1)

Line graph showing the mean severity of day heartburn over time by study day for evaluable patients, with severity scale from 0 (none) to 3 (severe). The graph compares placebo with Lansoprazole 15 mg and 30 mg administered once daily (QD) over approximately 55 days from start of treatment. Both Lansoprazole doses show a marked decrease in mean severity compared to placebo.*

FDA Label Image

Figure2 (Lansoprazole Fig2)

Line graph displaying mean severity of night heartburn scores over days from treatment start. It compares placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD, showing decreasing symptom severity over time, with Lansoprazole 30 mg QD showing the greatest reduction.*

FDA Label Image

Package Label-principal Display Panel (15 mg Blister Carton 100 (10 x 10) Unit-dose Tablets)

Packaging label for Lansoprazole Delayed-Release Orally Disintegrating Tablets, 15 mg strength. The label shows the product as delayed-release, orally disintegrating tablets, with 100 unit-dose tablets per package (10 x 10). Labeler is Aurobindo Pharma Limited, and it is for Rx only. The label includes pharmacist instructions and storage information, with distribution noted as Aurobindo Pharma USA, Inc., made in India.*

FDA Label Image

Package Label-principal Display Panel (30 mg Blister Carton 100 (10 x 10) Unit-dose Tablets)

Carton label for Lansoprazole Delayed-Release Orally Disintegrating Tablets, 30 mg strength. The label indicates the product is for prescription use only and contains 100 unit-dose tablets (10 x 10). Labeler is Aurobindo Pharma Limited. The label includes directions for use, storage instructions, and contains a barcode and distribution information for Aurobindo Pharma USA, Inc.*

FDA Label Image

Chemical Structure (Lansoprazole Str)

Chemical structure of Lansoprazole, showing its molecular framework including the benzimidazole ring and substituted pyridine moiety linked by a sulfinyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.